IL13 and Alzheimer disease: The relationship between reduced DNA methylation in the IL13 promoter of AD patients and increased IL-13 expression support that this cytokine is a central pathogenic mediator in AD45 and therapies targeting this molecule or its receptors (e.g. Dupilumab) might be beneficial in patients with severe atopic phenotypes46.